219 related articles for article (PubMed ID: 19519284)
1. Overview of the changing epidemiology of candidemia.
Lewis RE
Curr Med Res Opin; 2009 Jul; 25(7):1732-40. PubMed ID: 19519284
[TBL] [Abstract][Full Text] [Related]
2. [Nosocomial candidemia: new challenges of an emergent problem].
Gómez J; García-Vázquez E; Hernández A; Espinosa C; Ruiz J
Rev Esp Quimioter; 2010 Dec; 23(4):158-68. PubMed ID: 21191553
[TBL] [Abstract][Full Text] [Related]
3. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.
Playford EG; Marriott D; Nguyen Q; Chen S; Ellis D; Slavin M; Sorrell TC
Crit Care Med; 2008 Jul; 36(7):2034-9. PubMed ID: 18552700
[TBL] [Abstract][Full Text] [Related]
4. Candidemia in children.
Zaoutis T
Curr Med Res Opin; 2010 Jul; 26(7):1761-8. PubMed ID: 20513207
[TBL] [Abstract][Full Text] [Related]
5. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
7. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome.
Dimopoulos G; Ntziora F; Rachiotis G; Armaganidis A; Falagas ME
Anesth Analg; 2008 Feb; 106(2):523-9, table of contents. PubMed ID: 18227310
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
9. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier C; Hart E; Lefort A; Ribaud P; Dromer F; Denning DW; Lortholary O
J Antimicrob Chemother; 2006 Mar; 57(3):384-410. PubMed ID: 16449304
[TBL] [Abstract][Full Text] [Related]
11. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection.
Klevay MJ; Horn DL; Neofytos D; Pfaller MA; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):152-7. PubMed ID: 19376667
[TBL] [Abstract][Full Text] [Related]
12. Invasive Candida infections: the changing epidemiology.
Marr KA
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 13):9-14. PubMed ID: 15682589
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients.
Davis SL; Vazquez JA; McKinnon PS
Ann Pharmacother; 2007 Apr; 41(4):568-73. PubMed ID: 17374623
[TBL] [Abstract][Full Text] [Related]
14. New developments in the diagnosis and management of invasive fungal infections.
De Marie S
Haematologica; 2000 Jan; 85(1):88-93. PubMed ID: 10629598
[TBL] [Abstract][Full Text] [Related]
15. Echinocandins: pharmacokinetic and therapeutic issues.
Cleary JD
Curr Med Res Opin; 2009 Jul; 25(7):1741-50. PubMed ID: 19557937
[TBL] [Abstract][Full Text] [Related]
16. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals.
Bassetti M; Trecarichi EM; Righi E; Sanguinetti M; Bisio F; Posteraro B; Soro O; Cauda R; Viscoli C; Tumbarello M
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):325-31. PubMed ID: 17350205
[TBL] [Abstract][Full Text] [Related]
17. Current treatment strategies for disseminated candidiasis.
Spellberg BJ; Filler SG; Edwards JE
Clin Infect Dis; 2006 Jan; 42(2):244-51. PubMed ID: 16355336
[TBL] [Abstract][Full Text] [Related]
18. Could risk assessment for non-albicans Candida improve empiric treatment for invasive candidiasis?
Drew RH
Ann Pharmacother; 2007 Apr; 41(4):690-2. PubMed ID: 17389669
[TBL] [Abstract][Full Text] [Related]
19. The changing epidemiology of invasive fungal infections: new threats.
Maschmeyer G
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():3-6. PubMed ID: 16707250
[TBL] [Abstract][Full Text] [Related]
20. Invasive candidiasis and candidemia: new guidelines.
De Rosa FG; Garazzino S; Pasero D; Di Perri G; Ranieri VM
Minerva Anestesiol; 2009; 75(7-8):453-8. PubMed ID: 19078900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
